Automated Bio-banking Market Revenue to Attain USD 6.52 Bn by 2033

10 Oct 2025

Share :

Table of Content

1. Automated Bio-banking Market Revenue and Trends 2025 to 2033 2. What is Fueling the Rise of the Automated Bio-banking Market? 3. Segmental Analysis  4. Regional Analysis 5. Automated Bio-banking Market Coverage 6. Automated Bio-banking Market Companies

Automated Bio-banking Market Revenue and Trends 2025 to 2033

The global automated bio-banking market revenue reached USD 2.73 billion in 2025 and is predicted to attain around USD 6.52 billion by 2033 with a CAGR of 11.48%. The automated bio-banking market is driven by increasing demand for high-throughput sample storage, advanced laboratory automation, and the need for secure, efficient biobanking solutions.

What is Fueling the Rise of the Automated Bio-banking Market?

The automated bio-banking market is experiencing significant growth primarily due to the growing acceptance of automation in the sample storage, retrieval, and management processes. Automated bio-banking incorporates the use of robots, software, and data management tools to handle biological samples for use in areas such as clinical research, genomics, and drug discovery.

Automation improves accuracy, reduces human error, and allows the storage of high-throughput samples in larger biorepositories. The increasing demand for personalized medicine, for biopharmaceutical research, and the increasing need for high-throughput sample analysis are also driving growth. Globally, this is all being supported in enhancing automation through artificial intelligence and smart laboratory infrastructure

Segmental Analysis 

• By Product Type- Automated sample storage systems are the leading products in the segment; as these systems are efficient in preserving the integrity of samples, they minimize human handling mistakes and allow for high-throughput biorepository activities.
• By Sample Type –Blood products lead the segment as they are widely used in clinical research, disease identification, and therapeutic development, and require the need for large-scale traceable storage options.
• By Application- The drug discovery & development segment dominates as automated biobanks improves reproducibility, help retrieve samples faster, and speed up pharmaceutical R&D pre-clinical and clinical research work.
• By Automation Level –The automated bio-banking systems dominate the segment due to their higher precision and reduced human interaction with sensitive biological samples while maintaining consistent environmental conditions.
• By End-User- Pharmaceutical and biopharmaceutical companies are considered the predominant user because they have a wide-ranging requirement for high quality biological samples that have been well-preserved for the continuous development of their drug pipeline as well as to investigate biomarkers.
• By Storage Capacity –Medium-scale automated bio-banks dominate the storage capacity segment as they provide a balanced platform for storage capacity, cost, and operational effectiveness and are considered suitable for regional healthcare services or research organization activities.

Regional Analysis

North America is the leading automated biobanking region due to its strong healthcare ecosystem, highly-developed laboratory sets, and the large presence of biopharmaceutical companies. North America is particularly focused on precision medicine, genomics, and large clinical trials, thereby spurring the need for automated sample storage and retrieval systems. North America also maintains regulatory support, has a higher adoption of digital solutions, and demonstrates high investment in R&D, preserving its position as the world leader in biobanking automation.

Asia Pacific is quickly becoming the fastest-growing market due to the need for rapid investments in health care infrastructure and biomedical research. Countries like China, Japan, and India are accelerating the adoption of automated biobanking solutions in order to advance clinical trials, genomics, and large population studies. In addition to expanding government support, there is a growing interest in personalized medicine and enhanced collaboration between hospitals and research institutes to accelerate the adoption of automated biobanking systems. 

Automated Bio-banking Market Coverage

Automated Bio-banking Market Companies

• Thermo Fisher Scientific Inc.
• Azenta Life Sciences (formerly Brooks Life Sciences)
• Hamilton Company
• Tecan Group Ltd.
• Qiagen N.V.
• Greiner Bio-One International GmbH
• LiCONiC AG
• ASKION GmbH
• PHC Holdings Corporation (Panasonic Healthcare)
• BioCision, LLC
• Micronic Holding B.V.
• Biobank AS
• Ziath Ltd.
• Promega Corporation

Recent Developments

• In March 2025, Galatea Bio has secured $25 million in funding to enhance high-throughput sequencing, AI-driven genomic analysis, and global biobank expansion targeting underrepresented populations. (Source: https://galatea.bio)

Get this report to explore global market size, share, CAGR, and trends, featuring detailed segmental analysis and an insightful competitive landscape overview @ https://www.precedenceresearch.com/sample/6956

You can place an order or ask any questions, please feel free to contact us at sales@precedenceresearch.com |+1 804 441 9344